The radiopharmaceutical methylene diphosphonate (MDP) is a relatively new diagnostic tool and currently in widespread use as a gone imaging agent to delineate areas of altered osteogenesis. MDP is chelated with radioactive technetium-99m (Tc99m) and injected into the venous system of the body. It quickly clears from the bloodstream and is deposited into areas of bone transformation. Osteoporosis, primary carcinoma, bony metastases, osteomyelitis, and stress fractures are diagnosed with the use of Tc99m-MDP (1). In the presence of disease, the biodistribution of Tc99m-MDP is altered and this change is reflected in the images or scans. Ideally, the product would show a high ration of radioactivity in the target organ tot that of the surrounding tissue, with a minimization of radiation exposure to the patient. The purpose of this study will be to investigate Methylene Diphosphonate radiopharmaceuticals for their binding efficiencies, stability, and subsequent changes due to varying technetium levels.
| Identifer | oai:union.ndltd.org:pacific.edu/oai:scholarlycommons.pacific.edu:uop_etds-1483 |
| Date | 01 January 1985 |
| Creators | Costanzo, Jerry Lee |
| Publisher | Scholarly Commons |
| Source Sets | University of the Pacific |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | University of the Pacific Theses and Dissertations |
Page generated in 0.0019 seconds